A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Pamiparib (Primary) ; Temozolomide (Primary)
- Indications Advanced breast cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors BeiGene
- 30 Sep 2019 According to a BeiGene media release, as of July 29, 2019, a total of 113 patients with solid tumors have been enrolled in the study.
- 30 Sep 2019 Results presented in a BeiGene Media Release.
- 30 Sep 2019 According to a BeiGene media release, data were presented at the European Society for Medical Oncology (ESMO) Congress 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History